Livre Blanc
Understanding the Diverse CAGT Landscape in Asia Pacific
The APAC CAGT landscape, often perceived as uncertain, is primed for clinical research and market access success
Sep 23, 2021
Download

The last two decades have seen significant growth in cancer research with considerable advancements made in the cell and gene therapy (CAGT) field across the world. In Asia Pacific (APAC), the rapid expansion of innovative cancer treatments is expected to continue given the current clinical trial trends in the region, particularly pertaining to the potential and capability of the availability of centers, patient recruitment and regulatory landscape in key markets.

Featuring discussion and knowledge from an advisory board involving key opinion leaders (KOLs) across Australia, China, Japan, New Zealand, Singapore, South Korea and Taiwan, this white paper explores the growing success and potential of the CAGT market landscape in Asia Pacific. Download the white paper to find out how CAGT is transforming cancer treatment across the APAC region.

To learn more about IQVIA APAC’s CAGT solutions, please click here

Contact Us